MedTrace Logo

Effect of Oligopin® on Skin Ageing

NCT04141059 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2022-03-02

No results posted yet for this study

Summary

Extrinsic or exogenous ageing is caused by repetitive exposure of the skin to harmful agents, while primary cause the exposure to ultraviolet (UV) radiation, known as photoageing, including solar effect. Chronic solar UV exposure has multiple damaging effects on skin, such as wrinkling, dryness, dyspigmentation, epidermal thinning and increasing fragility. In addition, solar exposure and age increase a subepidermal band.

Fibrillar collagen, which is synthesized from fibroblasts, is the predominant extracellular matrix (ECM) component of the dermis. Collagen type I and III are considered to be the major interstitial, fiber forming collagen in normal human dermis. In addition, the dermis contains collagen types IV (gelatine), V and VI. Other important component of the EMC of the dermis are elastic fibers being elastin (ELN) their main component and play a critical role in skin elasticity and the reduction of elastic fiber production results in impaired elasticity. UV radiation induces ECM degeneration and consequently an increase in fragility and loss of elasticity of the skin. This process is mediated by an increase in matrix metalloproteinases (MMPs) expression in human skin which are responsible for degrading ECM proteins, such as collagen, fibronectin and elastin. The natural inhibitors of MMPs are tissue inhibitors of metalloproteinases (TIMPs), being TIMP-1 the most relevant TIMP affecting collagen metabolism.

Conditions

  • Skin Aging

Interventions

DIETARY_SUPPLEMENT

Oligopin

Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.

DIETARY_SUPPLEMENT

Placebo

Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate

Sponsors & Collaborators

  • Fundació Eurecat

    collaborator OTHER

  • Hospital Universitari Sant Joan de Reus

    collaborator OTHER

  • University Rovira i Virgili

    collaborator OTHER

  • Les Dérivés Résiniques et Terpéniques (DRT) S.A.S.

    collaborator UNKNOWN

  • Technological Centre of Nutrition and Health, Spain

    lead OTHER

Principal Investigators

  • Rosa Solà, Dr · UTNS (Eurecat_Reus)/HUSJR. Reus, Tarragona, Spain.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2020-09-10
Completion
2020-09-10

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141059 on ClinicalTrials.gov